Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Jonathan T Lei,Jieya Shao,Jin Zhang,Michael Iglesia,Doug W Chan,Jin Cao,Meenakshi Anurag,Purba Singh,Xiaping He,Yoshimasa Kosaka,Ryoichi Matsunuma,Robert Crowder,Jeremy Hoog,Chanpheng Phommaly,Rodrigo Goncalves,Susana Ramalho,Raquel Mary Rodrigues Peres,Nindo Punturi,Cheryl Schmidt,Alex Bartram,Eric Jou,Vaishnavi Devarakonda,Kimberly R Holloway,W Victoria Lai,Oliver Hampton,Anna Rogers,Ethan Tobias,Poojan A Parikh,Sherri R Davies,Shunqiang Li,Cynthia X Ma,Vera J Suman,Kelly K Hunt,Mark A Watson,Katherine A Hoadley,E Aubrey Thompson,Xi Chen,Shyam M Kavuri,Chad J Creighton,Christopher A Maher,Charles M Perou,Svasti Haricharan,Matthew J Ellis

DOI: https://doi.org/10.1016/j.celrep.2018.07.009

IF: 8.8

2018-01-01

Cell Reports

Abstract:RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor-positive (ER+) breast cancer, but their role in disease pathogenesis remains unclear. We examined multiple ESR1 fusions and found that two, both identified in advanced endocrine treatment-resistant disease, encoded stable and functional fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, ESR1 exons 1-6 were fused in frame to C-terminal sequences from the partner gene. Functional properties include estrogen-independent growth, constitutive expression of ER target genes, and anti-estrogen resistance. Both fusions activate a metastasis-associated transcriptional program, induce cellular motility, and promote the development of lung metastasis. ESR1-e6>YAP1- and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, and a patient-derived xenograft (PDX) naturally expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression, explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.